Aldeyra Therapeutics, INC. 8-K Filing

Ticker: ALDX · Form: 8-K · Filed: Nov 13, 2025 · CIK: 1341235

Aldeyra Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyAldeyra Therapeutics, INC. (ALDX)
Form Type8-K
Filed DateNov 13, 2025
Pages5
Reading Time6 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 8-K filing submitted by Aldeyra Therapeutics, INC. (ticker: ALDX) to the SEC on Nov 13, 2025.

What are the key financial figures in this filing?

Key dollar amounts include: $0.001 (e on which registered Common Stock, $0.001 par value per share ALDX The Nasdaq).

How long is this filing?

Aldeyra Therapeutics, INC.'s 8-K filing is 5 pages with approximately 1,512 words. Estimated reading time is 6 minutes.

Where can I view the full 8-K filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 1,512 words · 6 min read · ~5 pages · Grade level 15.8 · Accepted 2025-11-13 07:00:39

Key Financial Figures

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On November 13, 2025, Aldeyra Therapeutics, Inc. ("Aldeyra") intends to make a slide presentation at its previously announced 2025 Research & Development Webcast (the "2025 Research and Development Webcast"). A copy of Aldeyra's slide presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The furnishing of the attached slide presentation is not an admission as to the materiality of any information contained therein. The information contained in the slide presentation is summary information that is intended to be considered in the context of more complete information included in Aldeyra's filings with the Securities and Exchange Commission ("SEC") and other public announcements that Aldeyra has made and may make from time to time by press release or otherwise. Aldeyra undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Various statements to be made during the conference call are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Aldeyra's future expectations, plans, and prospects, including without limitation statements regarding: the goals, opportunity, and potential for Aldeyra's RASP modulator product candidates and pipeline; the outcome and timing of any clinical trials of Aldeyra's RASP modulator product candidates; anticipated timing of regulatory filings; and the outcome of the New Drug Application of reproxalap for the treatment of dry eye disease. Aldeyra intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward

01 Other Events

Item 8.01 Other Events. On November 13, 2025, Aldeyra issued a press release regarding the 2025 Research & Development Webcast (the "Press Release") including the expansion of the RASP platform to include central nervous system diseases, and manufacturing updates on reproxalap, a first-in-class investigational new drug candidate for the treatment of the signs and symptoms of dry eye disease. The Press Release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Slide Presentation of Aldeyra Therapeutics, Inc. dated November 13, 2025. 99.2 Press Release of Aldeyra Therapeutics, Inc. dated November 13, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALDEYRA THERAPEUTICS, INC. By: /s/ Todd C. Brady Name: Todd C. Brady, M.D., Ph.D. Title: Chief Executive Officer Dated: November 13, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing